ASCO 2026: LB2102 first-in-human ORR 28.6% in SCLC; new CARVYKTI data
Legend Biotech presented data on LB2102 (DLL3 CAR-T); CARVYKTI (cilta-cel) for Small cell lung cancer / LCNEC; multiple myeloma at a medical meeting on Jun 1, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Legend Biotech Corporation LEGN
- Drug
- LB2102 (DLL3 CAR-T); CARVYKTI (cilta-cel)
- For
- Small cell lung cancer / LCNEC; multiple myeloma
- Stage
- Phase 1 · an early safety study in a small group of people
- When
- Jun 1, 2026
- Source note
- Legend reported first-in-human results for DLL3-targeted CAR-T LB2102 in relapsed/refractory small cell lung cancer and LCNEC, with a 28.6% ORR and 78.6% disease control rate at higher dose levels. New CARTITUDE analyses reinforcing CARVYKTI durability were also presented.
- Checked
- Checked by a person when it was added
- Source: investors.legendbiotech.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- LEGN headlines on this site
Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Legend Biotech (in vivo CAR-T / pipeline for oncology and autoimmune): a step in the program rather than a decision or a data readout.
More details
- Entry
- Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026 · Company milestone
- Drug
- in vivo CAR-T / pipeline
- For
- oncology and autoimmune
- Stage
- IND
- When
- H2 2026 · the company gave a window, not a day
- Source note
- From Legend's JPM 2026 business update (Jan 12, 2026, via StockTitan mirror of company PR). The Aug 11, 2026 Q2 PR gave no dated forward milestones; LB2501 in vivo CAR-T PoC already reported at EHA 2026.
- Checked
- Checked by a person when it was added
- Verify it
- Source: stocktitan.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- LEGN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Legend Biotech expects to report results from its Phase 3 study of Carvykti (ciltacabtagene autoleucel) for Newly diagnosed multiple myeloma (transplant-ineligible: CARTITUDE-5; transplant-eligible: CARTITUDE-6) during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- CARTITUDE-5 and CARTITUDE-6 event-driven Phase 3 readouts: Carvykti in frontline multiple myeloma · Clinical trial results (readout / topline data)
- Drug
- Carvykti (ciltacabtagene autoleucel)
- For
- Newly diagnosed multiple myeloma (transplant-ineligible: CARTITUDE-5; transplant-eligible: CARTITUDE-6)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2027 · the company gave a window, not a day
- Source note
- Both J&J-partnered trials are fully enrolled but event-driven; management frames readouts as possible in 2026-2027 with no committed date. Dated 2027 as the midpoint of the guided window - treat as a floating catalyst.
- Checked
- Checked by a person when it was added
- Verify it
- Source: tipranks.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- LEGN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page